| Dr Nicholas W Frederickson, MD | |
|
901 Patients First Drive Suite 3300, Washington, MO 63090 | |
| (636) 239-7344 | |
| (636) 239-9436 |
| Full Name | Dr Nicholas W Frederickson |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 14 Years |
| Location | 901 Patients First Drive Suite 3300, Washington, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154640225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R-8906 (Iowa) | Secondary |
| 207RG0100X | Internal Medicine - Gastroenterology | 2016012330 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Washington | Washington, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Gastroenterology Llc | 8628121795 | 51 |
News Archive
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.
Elsewhere, a lawsuit accuses a big California insurer of deceptive enrollment practices, and consumers see that provider lists are often out-of-date and inaccurate.
In 2004 Robert Klein, chairman of the California Institute of Regenerative Medicine (CIRM), helped pass Proposition 71, establishing the CIRM with a state taxpayer-funded $3 billion budget for ten years. The measure was passed with promises of affordable cures for virtually all diseases, cures specifically from embryonic stem cells and cloning, as well as tremendous financial payback for the citizens of California. The Los Angeles Times recently noted that Klein plans to seek up to $3 billion more from state taxpayers for his stem cell fiefdom.
› Verified 3 days ago
| Entity Name | Mercy Clinic Gastroenterology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528295334 PECOS PAC ID: 8628121795 Enrollment ID: O20090806000762 |
News Archive
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.
Elsewhere, a lawsuit accuses a big California insurer of deceptive enrollment practices, and consumers see that provider lists are often out-of-date and inaccurate.
In 2004 Robert Klein, chairman of the California Institute of Regenerative Medicine (CIRM), helped pass Proposition 71, establishing the CIRM with a state taxpayer-funded $3 billion budget for ten years. The measure was passed with promises of affordable cures for virtually all diseases, cures specifically from embryonic stem cells and cloning, as well as tremendous financial payback for the citizens of California. The Los Angeles Times recently noted that Klein plans to seek up to $3 billion more from state taxpayers for his stem cell fiefdom.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas W Frederickson, MD 901 Patients First Drive Suite 3300, Washington, MO 63090 Ph: (636) 239-7344 | Dr Nicholas W Frederickson, MD 901 Patients First Drive Suite 3300, Washington, MO 63090 Ph: (636) 239-7344 |
News Archive
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.
Elsewhere, a lawsuit accuses a big California insurer of deceptive enrollment practices, and consumers see that provider lists are often out-of-date and inaccurate.
In 2004 Robert Klein, chairman of the California Institute of Regenerative Medicine (CIRM), helped pass Proposition 71, establishing the CIRM with a state taxpayer-funded $3 billion budget for ten years. The measure was passed with promises of affordable cures for virtually all diseases, cures specifically from embryonic stem cells and cloning, as well as tremendous financial payback for the citizens of California. The Los Angeles Times recently noted that Klein plans to seek up to $3 billion more from state taxpayers for his stem cell fiefdom.
› Verified 3 days ago
Dr. Isaac I Cohen, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 901 Patients First Drive, Washington, MO 63090 Phone: 636-390-1600 Fax: 636-390-1601 | |
Sudhanshu Gogia, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr, Washington, MO 63090 Phone: 636-239-7344 Fax: 636-239-9436 | |
Dr. John R Douglas Peterson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 3300, Washington, MO 63090 Phone: 636-239-7344 | |
Mohan Mallikarjuna Edupuganti, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 2500, Washington, MO 63090 Phone: 636-239-2711 | |
Dr. Roberto Pacheco-coronado, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 2500, Washington, MO 63090 Phone: 636-239-2711 | |
Lydia Luisa Archuleta, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 E 5th St, Washington, MO 63090 Phone: 636-239-8000 |